Total trials
79
Active
4
Phase 3
5
Total enrollment
6,052
Pipeline matrix
Showing 1 of 1 active programs · click any cell for trials
| Intervention | Early Phase 1 | Phase 1 | Phase 2 | Phase 3 | Phase 4 | N/A | Total |
|---|---|---|---|---|---|---|---|
| Empagliflozin 10 MG | — | — | — | — | — | 2 |
Next readouts
- 2026-07
Top conditions
- Stroke8
- Asthma6
- Sarcoidosis3
- Dementia3
- Hip Fractures2
- Diabetes2
- Healthy2
- Chronic Obstructive Pulmonary Disease2
Frequently asked questions about University of East Anglia
- How many clinical trials does University of East Anglia have on ClinicalTrials.gov?
- University of East Anglia is listed as the lead sponsor on 79 clinical trials in ClinicalTrials.gov, 4 of which are currently active (recruiting, enrolling, or ongoing).
- How many of University of East Anglia's trials are in Phase 3?
- 5 of University of East Anglia's trials are in Phase 3, spread across 1 active drug program.
- What therapeutic areas does University of East Anglia focus on?
- University of East Anglia's most-studied conditions on ClinicalTrials.gov are Stroke, Asthma, Sarcoidosis, Dementia, Hip Fractures.
- When are University of East Anglia's next clinical trial readouts?
- University of East Anglia has 1 upcoming primary-completion readout tracked here; the soonest is “EMPA-ESUS. a Randomised Control Trial to Investigate the Impact of Empagliflozin on Left Atrial Function in Patients with Embolic Stroke of Undetermined Source”, expected around 2026-07.